Similar articles for PMID: 22539590

Year	Number of Results
1999	1
2000	1
2004	1
2005	1
2006	5
2007	1
2009	5
2010	5
2011	4
2012	10
2013	12
2014	6
2015	4
2016	1
2017	3
2018	2
2019	2
2021	1
2024	0

1

Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.

Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R; T-Emerge 3 Study Group. Henry RR, et al. J Clin Endocrinol Metab. 2012 Jul;97(7):2370-9. doi: 10.1210/jc.2011-3253. Epub 2012 Apr 26. J Clin Endocrinol Metab. 2012. PMID: 22539590 Clinical Trial.

2

Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).

Pratley RE, Urosevic D, Boldrin M, Balena R; T-emerge 6 Study Group. Pratley RE, et al. Diabetes Obes Metab. 2013 Mar;15(3):234-40. doi: 10.1111/dom.12009. Epub 2012 Sep 30. Diabetes Obes Metab. 2013. PMID: 22958426 Clinical Trial.

3

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.

Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, Reinhardt RR, Bode BW. Reusch J, et al. Diabetes Obes Metab. 2014 Dec;16(12):1257-64. doi: 10.1111/dom.12382. Epub 2014 Oct 6. Diabetes Obes Metab. 2014. PMID: 25155146 Clinical Trial.

4

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. DeFronzo RA, et al. J Clin Endocrinol Metab. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14. J Clin Endocrinol Metab. 2012. PMID: 22419732 Clinical Trial.

5

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.

Perez A, Zhao Z, Jacks R, Spanheimer R. Perez A, et al. Curr Med Res Opin. 2009 Dec;25(12):2915-23. doi: 10.1185/03007990903350011. Curr Med Res Opin. 2009. PMID: 19827910 Clinical Trial.

6

Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).

Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX, Balena R. Hollander P, et al. Obesity (Silver Spring). 2013 Feb;21(2):238-47. doi: 10.1002/oby.20042. Obesity (Silver Spring). 2013. PMID: 23404788 Free article. Clinical Trial.

7

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG PIO™ trial investigators. Kovacs CS, et al. Diabetes Obes Metab. 2014 Feb;16(2):147-58. doi: 10.1111/dom.12188. Epub 2013 Aug 22. Diabetes Obes Metab. 2014. PMID: 23906415 Clinical Trial.

8

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.

Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Nauck MA, et al. Diabetes Care. 2009 Jul;32(7):1237-43. doi: 10.2337/dc08-1961. Epub 2009 Apr 14. Diabetes Care. 2009. PMID: 19366970 Free PMC article. Clinical Trial.

9

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, Hanefeld M. Bolli GB, et al. Diabet Med. 2014 Feb;31(2):176-84. doi: 10.1111/dme.12328. Epub 2013 Oct 24. Diabet Med. 2014. PMID: 24117597 Free article. Clinical Trial.

10

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Schernthaner G, et al. J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76. doi: 10.1210/jc.2003-030861. J Clin Endocrinol Metab. 2004. PMID: 15579760 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

55 results

Results by year